Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STM-416 in Recurrent High-Grade Papillary Bladder Cancer
NCT05710848Phase 2Recruiting
- Sponsor
- SURGE Therapeutics
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of STM-416 in non-muscle-invasive bladder cancer (NMIBC), sponsored by SURGE Therapeutics. Started Jul 2023; status: recruiting.
02
Drugs
STM-416
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05710848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710848.